Effect of citalopram on brain serotonin release in experimental hepatic encephalopathy: Implications for thymoleptic drug safety in liver insufficiency

Clinical Neuropharmacology

Volumn 20, Issue 6, 1997, Pages 511-522

  Bergqvist, Peter B F ^a,c   Wikell, Cecilia ^a   Hjorth, Stephan ^b   Apelqvist, Gustav ^a   Bengtsson, Finn ^a  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Citalopram; Drug safety; Hepatic encephalopathy; Reuptake; Serotonin

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEPOLARIZATION; DRUG EFFECT; HEPATIC ENCEPHALOPATHY; LIVER FAILURE; MALE; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; RAT; SEROTONIN RELEASE; SEROTONINERGIC SYSTEM;

EID: 0030830683     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-199712000-00003     Document Type: Article

References (38)

1. Sherlock S, Summerskill WHJ, White LP, Phear EA. Portal-systemic encephalopathy. Neurological complications of liver disease. Lancet 1954;2:453-7.
2. Conn HO, Liebertahl MM, eds. The Hepatic Coma Syndromes and Lactulose. Baltimore: Williams & Wilkins; 1979.
3. Lee SH, Fisher B. Portacaval shunt in the rat. Surgery 1961;50:668-72.
4. Bengtsson F, Bugge M, Brun A, Falck B, Henriksson KG, Nobin A. The impact of time after portacaval shunt in the rat on behavior, brain serotonin, and brain and muscle histology. J Neurol Sci 1988;83:109-22.
5. Bengtsson F. Neurotransmission failure in hepatic encephalopathy involving the combined action of different brain tryptophan-related pathology: a speculative synthesis. In: Ishiguro I, Nagatsu T, Nagamura Y, eds. Advances in Tryptophan Research 1992. Toyoake, Japan: Fujita Health University Press; 1992:303-8.
6. Mousseau DD, Butterworth RF. Current theories on the pathogenesis of hepatic encephalopathy. Exp Biol Med 1994;206:329-44.
7. Bengtsson F, Bugge M, Johansen KH, Butterworth RF. Brain tryptophan hydroxylation in the portacaval shunted rat: a hypothesis for the regulation of serotonin turnover in vivo. J Neurochem 1991;56:1069-74.
8. Bengtsson F, Bergqvist PBF. Neuropsychiatric implications of brain tryptophan: pertubations appearing in hepatic encephalopathy. In: Allegri Filippini G, Costa CVL, eds. Recent Advances in Tryptophan Research. New York: Plenum; 1996:387-95.
9. Mans AM, Biebuyck JF, Davis DW, Hawkins RA. Portcaval anastomosis: brain and plasma metabolite abnormalities and the effect of nutritional therapy. J Neurochem 1984;43:697-705.
10. Bergqvist PBF, Vogels BAPM, Bosman DK, et al. Neocortical dialysate monoamines of rats after acute, subacute, and chronic liver shunt. J Neurochem 1995;64:1238-44.
11. Bergqvist PBF, Heyes MP, Apelqvist G, Butterworth RF, Bengtsson F. Brain extracellular quinolinic acid in chronic experimental hepatic encephalopathy as assessed by in vivo microdialysis: acute effects of L-tryptophan. Neuropsychopharmacology 1996;15:382-9.
12. Bengtsson F, Bugge M, Nobin A. Hepatocerebral dysfunction and brain serotonin. In: Butterworth RF, Pomier Layrargues G, eds. Hepatic Encephalopathy: Pathophysiology and Treatment. Clifton: Humana Press; 1989:355-87.
13. Bergqvist PBF, Hjorth S, Apelqvist G, Bengstsson F. Acute effects of L-tryptophan on the brain extracellular 5-HT and 5-HIAA levels in chronic experimental portal-systemic encephalopathy. Metab Brain Dis 1996;11:269-78.
14. Bergqvist PBF, Hjorth S, Audet R, Apelqvist G, Bengtsson F, Butterworth RF. Ammonium acetate challenge in experimental hepatic encephalopathy induces a transient increase of brain 5HT release in vivo. Eur Neuropsychopharmacology 1996;6:317-322.
15. Bergqvist PBF, Hjorth S, Apelqvist G, Bengtsson F. Potassium-evoked neuronal release of serotonin in experimental chronic portal-systemic encephalopathy. Metab Brain Dis 1997;12.
16. Bergqvist PBF, Hjorth S, Wikell C, Apelqvist G, Bengtsson F. p-Chloroamphetamine- and d-flenfluramine- induced brain serotonin release in experimental portal-systemic encephalopathy. 1997 Metab Brain Dis (in press).
17. Hyttel J. Citalopram: pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog Neuropsychopharmacol Biol Psychiatry 1982;6:277-95.
18. 1B autoreceptor blocking properties of the beta adrenoceptor antagonist (-)penbutolol. J Pharmacol Exp Ther 1993;265:707-712.
19. Schröder R. Müller O, Bircher J. The portacaval and splenocaval shunt in the normal rat. A morphometric and functional reevaluation. J Hepatol 1985;1:107-123.
20. Aghajanian GK. Feedback regulation of central monoaminergic neurons: evidence from single cell recording studies. In: Youdim MBH, Lovenberg W, Sharman DF, Lagnado JR, eds. Essays in Neurochemistry and Neuropharmacology. New York: Wiley, 1987:2-32.
21. 1A autoreceptors in the action of selective serotonin reuptake inhibitors. Eur J Pharmacol 1994;260:251-5.
22. Auerbach SB, Lundberg JF, Hjorth S. Differential inhibition of serotonin release by 5-HT and NA reuptake blockers after systematic administration. Neuropharmacology 1995;34:89-96.
23. Apelqvist G, Bergqvist PBF, Larsson B, Bugge M, Bengtsson F. Regional brain serotonin receptor changes in chronic experimental hepatic encephalopathy. 1997 (submitted for publication).
24. Baumann P, Larsen F. The pharmacokinetics of citalopram. Rev Contemp Pharmacother 1995;6:287-95.
25. Holm E, Jacob S, Kortsik C, Leweling H, Fischer B. Failure of selective serotonin reuptake inhibition to worsen the mental state of patients with subclinical hepatic encephalopathy. In: Soeters PB, Wilson JHP, Meijer AJ, Holm E, eds. Advances in Ammonia Metabolism and Hepatic Encephalopathy. Amsterdam: Elsevier; 1988:474-86.
26. Doogan DP, Caillard V. Sertraline: a new antidepressant. J Clin Psychiatry 1988;49:46-51.
27. Schenker S, Bergstrom RF, Wolen RL, Lemberger L. Fluoxetine disposition and elimination in cirrhosis. Clin Pharmacol Ther 1988;44:353-9.
28. Krastev Z, Terzilivanov D, Vlahov V, et al. The pharmacokinetics of paroxetine in patients with liver cirrhosis. Acta Psychiatr Scand 1989;80:91-2.
29. Royer RJ, Royer-Morrot MJ, Paille F, et al. Tianeptine and its main metabolite pharmacokinetics in chronic alcoholism and cirrhosis. Clin Pharmacokinet 1989;16:186-91.
30. DeVane CL, Laizure SC, Stewart JT, et al. Disposition of bupropion in healthy volunteers and subjects with alcoholic liver disease. J Clin Psychopharmacol 1990;10:328-32.
31. Stoeckel K, Pfefen JP, Mayersohn M, et al. Absorption and disposition of moclobemide in patients with advanced age or reduced liver or kidney function. Acta Psychiatr Scand 1990;82:94-7.
32. Dalhoff K, Almdal TP, Bjerrum K, Keiding S, Mengel H, Lund J. Pharmacokinetics of paroxetine in patients with cirrhosis. Eur J Clin Pharmacol 1991;41:351-4.
33. Goodnick PJ. Pharmacokinetics of second generation antidepressants: fluoxetine. Psychopharmacol Bull 1991;27:503-12.
34. Ferry N, Bernard N, Cuisinaud G, Rougier P, Trepo C, Sassard J. Influence of hepatic impairment on the pharmacokinetics of nefazodone and two of its metabolites after single and multiple oral doses. Fundam Clin Pharmacol 1994;8:463-73.
35. Orlando R, Benvenuti C, Mazzo M, Palatini P. The pharmacokinetics of teniloxazine in healthy subjects and patients with hepatic cirrhosis. Br J Clin Pharmacol 1995;39:445-8.
36. Hale AS. New antidepressants: use in high-risk patients. J Clin Psychiatry 1993;54:61-70.
37. DeVane CL. Pharmacokinetics of newer antidepressants: clinical relevance. Am J Med 1994;97(suppl):13-23.
38. Holm E, Uhl W, Stamm S. Safety of fluvoxamine for patients with chronic liver disease: biochemical variables, psychometric performance and EEG. Adv Pharmacother 1986;2:151-65.